奥西多尔
化学
酰肼
激酶
受体酪氨酸激酶
癌症研究
药理学
选择性
生物化学
立体化学
生物
催化作用
有机化学
作者
J. Jean Cui,Michele A. McTigue,Mitchell D. Nambu,Michelle Tran‐Dubé,Mason Pairish,Hong Shen,Lei Jia,Hengmiao Cheng,Jacqui E. Hoffman,Phuong Le,Mehran Jalaie,Gilles H. Goetz,Kevin Ryan,Neil B. Grodsky,Ya‐Li Deng,Max Parker,Sergei L. Timofeevski,Brion William Murray,Shinji Yamazaki,Shirley A. Aguirre
摘要
The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole hydrazide hit 6 was identified during a c-MET HTS campaign and subsequently demonstrated to have an unusual degree of selectivity against a broad array of other kinases. The cocrystal structure of the related oxindole hydrazide c-MET inhibitor 10 with a nonphosphorylated c-MET kinase domain revealed a unique binding mode associated with the exquisite selectivity profile. The chemically labile oxindole hydrazide scaffold was replaced with a chemically and metabolically stable triazolopyrazine scaffold using structure based drug design. Medicinal chemistry lead optimization produced 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (2, PF-04217903), an extremely potent and exquisitely selective c-MET inhibitor. 2 demonstrated effective tumor growth inhibition in c-MET dependent tumor models with good oral PK properties and an acceptable safety profile in preclinical studies. 2 progressed to clinical evaluation in a Phase I oncology setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI